Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader with a category-defying portfolio, harnessing its generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its ~37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day.
Teva’s TEV-'248 is a potentially best-in-class fixed dose combination of fluticasone propionate/albuterol sulfate in a multidose dry powder inhaler being developed for the reduction and prevention of asthma exacerbations. The dual-Action Asthma Rescue Inhaler Program (ICS-SABA/TEV-’248) builds upon Teva’s existing expertise and wide portfolio in respiratory medicine including the ArmonAir (fluticasone proprionate) and ProAir (arlbuterol sulfate) product lines.
Launch Therapeutics and Teva have entered into a clinical collaboration agreement whereby Launch Therapeutics will lead the operational execution and management of the planned clinical trials.